Studying Patient Position and BCG Dwell Time for Bladder Cancer

This study is looking at how different body positions affect how long Bacillus Calmette Guerin (BCG) stays in your bladder when treating non-muscle invasive bladder cancer. BCG is a common treatment, and how long it stays in your bladder (called "dwell time") is important. You would receive BCG solution three times, each time with different instructions: once with no activity restrictions, once lying down, and once sitting. Researchers will use a Fitbit to track your activity. The goal is to see if certain positions help the BCG work better. This study plans to enroll 40 participants aged 18 and older who have not yet started BCG treatment for intermediate or high-risk non-muscle invasive bladder cancer.

Study design
This interventional study plans to enroll 40 participants. It will compare the effects of different patient positions during BCG treatment.
What's involved
You will receive BCG solution three times, each with different positioning instructions. You will also wear a Fitbit activity tracker for at least five days during the study.
Compensation
Not stated in the trial record.
Follow-up
BCG dwell time will be assessed up to 5 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07474519

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Recruiting
PHASE4Ages 18+InterventionalTreatment
Ohio State University Comprehensive Cancer Center
~40 participants
Updated 2026-03-16 on ClinicalTrials.gov
What's tested:AccelerometryBCG SolutionElectronic Health Record ReviewPatient DischargeSurvey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Bacillus Calmette Guerin (BCG) dwell time
Measured over From the instillation of the drug to the void time or 2 hours, whichever is earlier, assessed up to 5 weeks
Non-Muscle Invasive Bladder Carcinoma

NCT07474519

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohiostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Cheryl T Lee, MD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient with intermediate or high risk NMIBC opting for intravesical induction BCG
Has not initiated induction therapy
Able to remain in supine position for two hours. (Head may be raised on up to two pillows)
Able to remain in a sitting position for two hours
Willingness to utilize a wearable fitness tracker for at least five days during the study
Able to perform a remote video or telephone encounter
Able to provide informed consent

Exclusion

Receipt of intravesical BCG within the past 1 year
Known inability to retain BCG
History of urinary incontinence with a score of 3 or more on the Overactive Bladder Survey (OAB) urgency, urgency incontinence, or incontinence questions
Refusal to wear a fitness tracker during a 24-hour baseline, during treatment, and/or for 2 hours post treatment
  • Bacillus Calmette Guerin (BCG) dwell timeFrom the instillation of the drug to the void time or 2 hours, whichever is earlier, assessed up to 5 weeks

    Will be measured on the same participant under three test positions (ad lib, supine, and seated). A generalize linear mixed model for correlated data will be used to compare the three test conditions. Dwell time will be modeled as a function of test condition and any other covariates (i.e. patient characteristics and/or environmental aspects) thought to be related to dwell time. Interaction effects with test condition will be considered. If a majority of participants (\> 75%; n = 10) have dwell times of 2 hours, the statistical method used to compare the 3 test conditions will be changed. To determine factors that impact the ability to maintain the BCG for two hour, a generalized estimating equation (GEE) model will be used. The outcome of interest will be a binomial indicator of dwell time equal to (coded as 1) or less than (coded as 0) 2 hours. Covariates will include all patient characteristics, and any environmental aspects suspected of influencing dwell time.